Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 192
Filter
2.
Biomarkers ; 18(3): 196-203, 2013 May.
Article in English | MEDLINE | ID: mdl-23557128

ABSTRACT

CONTEXT: Endothelial function is abnormal in chronic obstructive pulmonary disease (COPD); whether endothelial dysfunction causes COPD is unknown. OBJECTIVE: Test associations of endothelial biomarkers with FEV1 using instrumental variables. METHODS: Among 26 907 participants with spirometry, ICAM-1, P-selectin, E-selectin and endothelin-1 were measured in subsets. RESULTS: ICAM-1 and P-selectin were inversely associated with FEV1 among European-Americans (-29 mL and -34 mL per standard deviation of log-transformed biomarker, p < 0.001), as was endothelin-1 among African-Americans (-22 mL, p = 0.008). Genetically-estimated ICAM-1 and P-selectin were not significantly associated with FEV1. The instrumental variable for endothelin-1 was non-informative. CONCLUSION: Although ICAM-1, P-selectin and endothelin-1 were inversely associated with FEV1, associations for ICAM-1 and P-selectin do not appear causal.


Subject(s)
Endothelium, Vascular/metabolism , Gene Expression , Lung/metabolism , Pulmonary Disease, Chronic Obstructive/genetics , Biomarkers/metabolism , Black People , Cohort Studies , E-Selectin/genetics , E-Selectin/metabolism , Endothelin-1/genetics , Endothelin-1/metabolism , Endothelium, Vascular/physiopathology , Female , Humans , Intercellular Adhesion Molecule-1/genetics , Intercellular Adhesion Molecule-1/metabolism , Lung/physiopathology , Male , Middle Aged , P-Selectin/genetics , P-Selectin/metabolism , Pulmonary Disease, Chronic Obstructive/ethnology , Pulmonary Disease, Chronic Obstructive/physiopathology , Respiratory Function Tests , Spirometry , White People
3.
J Hum Hypertens ; 27(8): 479-86, 2013 Aug.
Article in English | MEDLINE | ID: mdl-23514842

ABSTRACT

Drug therapy often fails to control hypertension. Azilsartan medoxomil (AZL-M) is a newly developed angiotensin II receptor blocker with high efficacy and good tolerability. This double-blind, controlled, randomised trial compared its antihypertensive efficacy and safety vs the angiotensin-converting enzyme inhibitor ramipril (RAM) in patients with clinic systolic blood pressure (SBP) 150-180 mm Hg. Patients were randomised (n=884) to 20 mg AZL-M or 2.5 mg RAM once daily for 2 weeks, then force-titrated to 40 or 80 mg AZL-M or 10 mg RAM for 22 weeks. The primary endpoint was change in trough, seated, clinic SBP. Mean patient age was 57±11 years, 52.4% were male, 99.5% were Caucasian. Mean baseline BP was 161.1±7.9/94.9±9.0 mm Hg. Clinic SBP decreased by 20.6±0.95 and 21.2±0.95 mm Hg with AZL-M 40 and 80 mg vs12.2±0.95 mm Hg with RAM (P<0.001 for both AZL-M doses). Adverse events leading to discontinuation were less frequent with AZL-M 40 and 80 mg (2.4% and 3.1%, respectively) than with RAM (4.8%). These data demonstrated that treatment of stage 1-2 hypertension with AZL-M was more effective than RAM and better tolerated.


Subject(s)
Angiotensin II Type 1 Receptor Blockers/therapeutic use , Angiotensin-Converting Enzyme Inhibitors/therapeutic use , Benzimidazoles/therapeutic use , Hypertension/drug therapy , Oxadiazoles/therapeutic use , Ramipril/therapeutic use , Double-Blind Method , Female , Humans , Male , Middle Aged
4.
Diabetes Obes Metab ; 15(7): 668-73, 2013 Jul.
Article in English | MEDLINE | ID: mdl-23489301

ABSTRACT

AIM: As there have been concerns that some classes or agents for the treatment of type 2 diabetes may increase CV risk, we evaluated the cardiovascular profile of the dipeptidyl peptidase-4 inhibitor alogliptin. METHODS: We evaluated the incidence of CV events in patients treated with alogliptin, placebo or comparator antihyperglycaemic drugs in the clinical trial database for alogliptin using the composite major adverse cardiovascular event (MACE) endpoints of CV death, non-fatal myocardial infarction and non-fatal stroke. RESULTS: The pooled analysis included 4168 patients exposed to alogliptin 12.5 and 25 mg daily for 2023 patient-years compared to 691 patients treated with placebo for 263 patient-years and 1169 patients treated with other antidiabetic agents (metformin, sulfonylureas and thiazolidinediones) for 703 patient-years. CV events were adjudicated by an expert endpoint committee blinded to treatment allocation. The incidence rates of the combined MACE were not significantly different between patients treated with alogliptin and comparator therapies (hazard ratio=0.635, 95% confidence interval, 0.0, 1.41). Additionally, other types of serious CV events were not significantly different between patients treated with alogliptin and comparator therapies. CONCLUSION: These analyses have not shown a signal of increased CV risk with alogliptin in patients with type 2 diabetes. Future results from the adequately powered EXAMINE trial will definitively assess the CV safety profile of aloglipin in patients with type 2 diabetes mellitus.


Subject(s)
Cardiovascular Diseases/chemically induced , Diabetes Mellitus, Type 2/drug therapy , Diabetic Angiopathies/chemically induced , Diabetic Cardiomyopathies/chemically induced , Dipeptidyl-Peptidase IV Inhibitors/adverse effects , Piperidines/adverse effects , Uracil/analogs & derivatives , Aged , Cardiovascular Diseases/complications , Cardiovascular Diseases/epidemiology , Cardiovascular Diseases/physiopathology , Cohort Studies , Diabetes Mellitus, Type 2/complications , Diabetic Angiopathies/epidemiology , Diabetic Angiopathies/physiopathology , Diabetic Cardiomyopathies/epidemiology , Diabetic Cardiomyopathies/physiopathology , Dipeptidyl-Peptidase IV Inhibitors/therapeutic use , Double-Blind Method , Female , Humans , Incidence , Male , Middle Aged , Piperidines/therapeutic use , Proportional Hazards Models , Severity of Illness Index , Uracil/adverse effects , Uracil/therapeutic use
5.
J Hum Hypertens ; 24(11): 749-54, 2010 Nov.
Article in English | MEDLINE | ID: mdl-20200549

ABSTRACT

Although it is known that reproducibility of ambulatory blood pressure (BP) is superior to office BP in middle-aged subjects, little is known in older age groups. Hence, we compared the long-term reproducibility of ambulatory and office BP readings in subjects over the age of 75 years. A cohort of 72 subjects 75-90 years of age (mean, 82 years at baseline) had repeat office and ambulatory BPs 2 years apart under similar conditions. On the same day, patients underwent office BP measurements by a semi-automated device and then by ambulatory BP monitoring. Awake and sleep periods were divided according to a diary kept by each patient. The agreement between studies was assessed using the standard deviation of the differences (SDD) and Bland-Altman plots. There were minimal mean changes in office, 24-h, and awake and sleep mean BP values between baseline and 2 years later. The SDDs between visits were lower for 24-h BP compared with the office BP (11.7/5.9 mm Hg versus 17.8/9.0 mm Hg, P<0.01). The SDD for 24-h BP was also lower than the SDDs for the awake and sleep BP (P<0.05). Nocturnal BPs defined by absolute values were more reproducible than categories of dippers and non-dippers. These data demonstrate that long-term reproducibility of 24-h BP is superior to office measurements for very elderly subjects. In a clinical trial involving this age group, far fewer subjects would be required if 24-h BP was the primary efficacy endpoint rather than the office BP.


Subject(s)
Blood Pressure Determination/methods , Blood Pressure Monitoring, Ambulatory , Blood Pressure , Health Services for the Aged , Office Visits , Age Factors , Aged , Aged, 80 and over , Brain/pathology , Circadian Rhythm , Cognition , Cohort Studies , Humans , Magnetic Resonance Imaging , Predictive Value of Tests , Reproducibility of Results , Time Factors
6.
J Hum Hypertens ; 23(12): 817-25, 2009 Dec.
Article in English | MEDLINE | ID: mdl-19357698

ABSTRACT

The antihypertensive effects of telmisartan 80 mg versus valsartan 160 mg, both combined with hydrochlorothiazide (HCTZ) 25 mg, were assessed in a pooled analysis from two large trials with identical study designs in patients with stage 1-2 hypertension. The trials were double-blind with a 4:4:1 randomization scheme to compare once-daily telmisartan 80 mg and HCTZ 25 mg versus once-daily valsartan 160 mg and HCTZ 25 mg versus once-daily placebo on reductions in clinic blood pressure (BP). The primary end point was changes from baseline in BP at the end of 8 weeks. In total, 2121 patients were randomized (telmisartan-HCTZ, 942, valsartan-HCTZ, 952, and placebo, 227) and had baseline seated BPs of 154/102 and 155/102 mm Hg in the two studies, respectively. Changes from baseline in BP after administration of telmisartan-HCTZ (-24.5/-18.0 mm Hg) were significantly greater than for both placebo (-4.1/-6.5 mm Hg) and valsartan-HCTZ (-22.3/-16.8 mm Hg) (versus placebo, P<0.0001 for systolic and diastolic BP; versus valsartan-HCTZ, P=0.0004 for systolic BP and P=0.0019 for diastolic BP). Adverse event rates were higher in the placebo group than in the active treatment groups (placebo, 41%, telmisartan-HCTZ, 30%, and valsartan-HCTZ, 30%, P<0.05). These data confirm that telmisartan-HCTZ at doses of 80/25 mg lowered systolic and diastolic BP to a greater extent than valsartan-HCTZ at doses of 160/25 mg in stage 1-2 hypertension. The magnitude of the BP-lowering effect provides support for the use of angiotensin receptor blockers with higher doses of a thiazide diuretic (25 mg) to improve hypertension control.


Subject(s)
Angiotensin-Converting Enzyme Inhibitors/administration & dosage , Benzimidazoles/administration & dosage , Benzoates/administration & dosage , Diuretics/administration & dosage , Hydrochlorothiazide/administration & dosage , Hypertension/drug therapy , Tetrazoles/administration & dosage , Valine/analogs & derivatives , Adult , Age Factors , Angiotensin-Converting Enzyme Inhibitors/adverse effects , Benzimidazoles/adverse effects , Benzoates/adverse effects , Blood Pressure/drug effects , Diuretics/adverse effects , Drug Therapy, Combination , Female , Humans , Hydrochlorothiazide/adverse effects , Male , Middle Aged , Racial Groups , Sex Factors , Telmisartan , Tetrazoles/adverse effects , Treatment Outcome , Valine/administration & dosage , Valine/adverse effects , Valsartan
7.
J Hum Hypertens ; 22(8): 559-68, 2008 Aug.
Article in English | MEDLINE | ID: mdl-18463672

ABSTRACT

Angiotensin-converting enzyme inhibitors combined with higher doses of hydrochlorothiazide (HCT), that is, 25 mg daily, have been recognized as an effective form of antihypertensive therapy. To evaluate the coadministration of 20 mg ramipril with 25 mg HCT, we carried out a randomized, double-blind, controlled trial with two dose schedules of ramipril (20 mg q.d. and 10 mg b.i.d.) and HCT monotherapy arms as comparators in 354 patients with stage 2 hypertension. The clinic blood pressure (BP) was assessed using a semiautomatic digital device and 24-h BP was measured using ambulatory BP recordings at baseline and after 8 weeks of therapy. At baseline, the demographics and baseline BP values were similar in the four treatment groups (age: 51-53 years, 52-58% male, 64-68% non-black, clinic BP: 155-158/103-104 mm Hg). Ramipril-HCT induced significantly greater reductions in both the clinic and ambulatory BP than the HCT and ramipril monotherapy treatments (for example, additional reductions in ambulatory BP on ramipril-HCT ranged from -7.3/-5.2 to -10.3/-7.4 mm Hg compared to the monotherapies, all P<0.001). Reductions from baseline were still numerically greater for the clinic BPs derived from device measurements than those for the BP values derived from 24-h ambulatory BP measurements (changes in clinic diastolic BP ranged from -8.5 to -15.5 mm Hg across treatment groups, whereas changes in ambulatory diastolic BP were -4.7 to -12.0 mm Hg for the same groups). Thus, these data support the use of ambulatory BP monitoring even when automated BP devices are used for the assessment of clinical BP in trials that attempt to differentiate BP responses among active comparator groups. In conclusion, based on its efficacy and tolerability profile the combination of ramipril and HCT was shown to be effective therapy for the treatment of stage 2 hypertension.


Subject(s)
Angiotensin-Converting Enzyme Inhibitors/therapeutic use , Blood Pressure Determination/statistics & numerical data , Blood Pressure/drug effects , Diuretics/therapeutic use , Hydrochlorothiazide/therapeutic use , Hypertension/physiopathology , Ramipril/therapeutic use , Angiotensin-Converting Enzyme Inhibitors/administration & dosage , Blood Pressure/physiology , Diuretics/administration & dosage , Dose-Response Relationship, Drug , Double-Blind Method , Drug Therapy, Combination , Female , Follow-Up Studies , Humans , Hydrochlorothiazide/administration & dosage , Hypertension/drug therapy , Male , Middle Aged , Ramipril/administration & dosage , Treatment Outcome
8.
Climacteric ; 10 Suppl 1: 25-31, 2007 Feb.
Article in English | MEDLINE | ID: mdl-17364595

ABSTRACT

Hypertension is one of the most important risk factors for the development of cardiovascular disease. The prevalence of hypertension increases with age and also after the menopause; therefore, blood pressure monitoring and effective control of elevated blood pressure are very important in postmenopausal women. The knowledge that aldosterone is a dual cardiovascular and endocrine hormone has blurred the once distinct boundary between gynecology and cardiovascular medicine. Aldosterone plays a major role in salt and water homeostasis, but also binds to mineralocorticoid receptors in the cardiovascular system, leading to structural and functional changes and consequent organ damage. Highly selective aldosterone blockade via the mineralocorticoid receptor has long-term antihypertensive effects. Drospirenone is a novel progestogen with aldosterone receptor antagonism (PARA), and therefore has antihypertensive effects through reduced salt and water retention. A new hormone therapy that combines 17beta-estradiol with drospirenone has been shown in several clinical studies to have a blood pressure-lowering effect in postmenopausal women with elevated blood pressure, in addition to effectively relieving symptoms of the menopause. These findings suggest a potential additional benefit on the cardiovascular system for the drospirenone/17beta-estradiol combination in the treatment of women with menopausal symptoms and elevated blood pressure.


Subject(s)
Androstenes/therapeutic use , Antihypertensive Agents/therapeutic use , Estradiol/therapeutic use , Estrogen Replacement Therapy , Hypertension/drug therapy , Blood Pressure/drug effects , Drug Combinations , Female , Humans , Postmenopause
9.
Kidney Int ; 71(9): 855-60, 2007 May.
Article in English | MEDLINE | ID: mdl-17377513

ABSTRACT

The circadian blood pressure (BP) rhythm is associated with worsened cardiovascular outcomes in patients who have an excessive morning BP surge and in those who lack the normal nocturnal BP fall (non-dippers). There are multiple pathophysiologic mechanisms underlying abnormalities in circadian BP, most importantly abnormalities in sympathetic nervous system activity, salt and volume balance, and activation of the renin-angiotensin system. Several of these factors can be modified by clinical interventions, either related to lifestyle changes and/or antihypertensive drug therapy. The timing of drug administration or specific drug delivery systems that lead to a greater effect at night and/or mitigate the early morning BP surge can correct abnormal circadian rhythms. Although these strategies have not yet been shown to alter clinical outcomes, it is reasonable to understand their biologic basis and take them into consideration when designing antihypertensive therapy.


Subject(s)
Blood Pressure/physiology , Circadian Rhythm/physiology , Sleep/physiology , Autonomic Nervous System/physiology , Diet , Humans , Hypertension/physiopathology , Renin-Angiotensin System/physiology , Sympathetic Nervous System/physiology
10.
J Hum Hypertens ; 17(12): 819-22, 2003 Dec.
Article in English | MEDLINE | ID: mdl-14704725

ABSTRACT

Traditional blood pressure (BP) methodology is subject to observer error such as terminal digit preference and single number preference leading to inaccuracies in measurement. A high percentage (60-90%) of terminal BP readings digit being zero has been reported from general medical- and hospital-based clinics. This study examined terminal digit preference in a hypertension specialty practice and assessed clinical factors that may be associated with zero preference in this setting. A retrospective chart review of patients presenting to the hypertension clinic at the University of Connecticut Health Center during the month of September 2001 was performed. Data were extracted on age, gender, height, weight, treatment status, and systolic and diastolic BP measurements taken by nursing staff and attending physicians. Terminal digit preference was apparent in BP readings taken by both nursing staff and physicians. Zero was the terminal systolic BP digit in 40% of readings taken by the nursing staff and 31% of readings taken by physicians. For diastolic BP readings, the percentages were 23 and 36%, respectively. Nurses also recorded 43% of diastolic BP readings with terminal digit 2. Age was significantly higher in those persons in whom the physician diastolic BP terminal digit was zero than in those with nonzero terminal digits (67+/-14 vs 59+/-18 years, P=0.008). Body mass index was lower in the patient group with diastolic terminal digit zero bias compared to those with nonzero terminal digits (28+/-5 vs 32+/-6 kg/m(2), P=0.02). In conclusion, although the frequency of zero digit preference did not reach the 60-80% levels found in previous studies, there was evidence of terminal digit preference in the systolic and diastolic measurements taken by nursing staff and attending physicians in a specialist hypertension clinic. We believe that the lower levels of terminal digit preference observed are an effect of increased training in proper BP measurement and technique. However, the observed bias in measurement even in a hypertension unit argues for regular monitoring and feedback to minimize such errors.


Subject(s)
Blood Pressure Determination/standards , Hypertension/diagnosis , Aged , Bias , Female , Humans , Logistic Models , Male , Medicine , Middle Aged , Office Visits , Quality Control , Retrospective Studies , Specialization , Sphygmomanometers
13.
Am Heart J ; 142(6): 1010-5, 2001 Dec.
Article in English | MEDLINE | ID: mdl-11717605

ABSTRACT

BACKGROUND: Our purpose was to study the safety of controlled-onset, extended-release (COER) verapamil in patients with hypertension or coronary artery disease, with a focus on elderly patients. METHODS: Adverse event data were pooled from 7 double-blind, multicenter, randomized trials including 1999 patients with hypertension or chronic stable angina pectoris. There were 1042 patients who received COER verapamil 180 to 540 mg once daily in the evening for up to 10 weeks, 373 patients who received placebo, and 584 who received an active comparator agent. Data were analyzed according to the following groups: all patients, patients with hypertension, patients with angina, older patients (>/=65 years old), and younger patients (<65 years old). Adverse event rates were compared across the treatment groups by the Fisher exact test. RESULTS: In all patients combined, the incidence of constipation (13% vs 2%), dizziness (6% vs 2%), and back pain (3% vs 1%) was higher in patients treated with COER verapamil than with placebo. Patients with hypertension had more back pain (4% vs 1%) and constipation (12% vs 1%) with COER verapamil than with placebo, whereas patients with angina had more bradycardia (2.6% vs 0%), dizziness (8% vs 2%), and constipation (15% vs 3%). Older patients treated with COER verapamil had more bradycardia, constipation, dizziness, and fatigue and had fewer headaches compared with younger patients treated with COER verapamil. Second- or third-degree atrioventricular block was not observed after administration of COER verapamil in any subgroup. CONCLUSION: These data demonstrate that COER verapamil has an acceptable safety profile that is largely unrelated to age in patients with hypertension or coronary artery disease.


Subject(s)
Angina Pectoris/drug therapy , Constipation/prevention & control , Hypertension/drug therapy , Verapamil/administration & dosage , Verapamil/adverse effects , Adult , Aged , Aged, 80 and over , Back Pain/chemically induced , Constipation/chemically induced , Delayed-Action Preparations , Dizziness/chemically induced , Female , Humans , Male , Middle Aged
14.
Am J Hypertens ; 14(9 Pt 1): 942-9, 2001 Sep.
Article in English | MEDLINE | ID: mdl-11587162

ABSTRACT

BACKGROUND: Smoking and hypertension interact to increase the incidence of cardiovascular disease; however, little is known about the effects of smoking cessation on blood pressure (BP) control. We prospectively evaluated the impact of smoking cessation on clinic and ambulatory BP and heart rate (HR) in stage 1 hypertensive and normotensive postmenopausal women. METHODS: A total of 66 women were randomly assigned using a 3:1 randomization scheme to immediate smoking cessation or to a wait list control group. Clinic and ambulatory BP and HR, and 24-h urinary catecholamine concentrations were obtained at baseline and again at 6 weeks. Carbon monoxide levels and self-report were used to assess compliance with smoking cessation. RESULTS: Ambulatory monitoring showed that the awake SBP decreased by 3.6+/-1.9 mm Hg in the treated subjects who quit smoking (n=19), whereas in the control group (n=15) there was an increase of 1.7+/-2.4 mm Hg (P=.045). Awake HR decreased after smoking cessation by 7+/-1 beats/min and did not change (0+/-1 beat/min) in the control group (P=.001). Blood pressure and HR did not significantly change during sleep after smoking cessation. Changes in the awake HR correlated with changes in urinary epinephrine concentrations (r= 0.58, P=.001), and norepinephrine concentrations (r= 0.45, P=.001), There was no significant change in clinic systolic BP, diastolic BP, or HR between groups. CONCLUSIONS: Smoking cessation reduces systolic BP and HR during the daytime, when patients typically smoke. These hemodynamic changes are due in part to reductions in sympathetic nervous system activity.


Subject(s)
Blood Pressure Monitoring, Ambulatory , Blood Pressure/physiology , Heart Rate/physiology , Postmenopause/physiology , Smoking Cessation , Women's Health , Aged , Antihypertensive Agents/therapeutic use , Carbon Monoxide/analysis , Catecholamines/urine , Circadian Rhythm/physiology , Connecticut/epidemiology , Cotinine/blood , Drug Therapy, Combination , Female , Follow-Up Studies , Humans , Hypertension/drug therapy , Hypertension/physiopathology , Middle Aged , Prospective Studies
15.
Blood Press Monit ; 6(2): 63-72, 2001 Apr.
Article in English | MEDLINE | ID: mdl-11433126

ABSTRACT

The incidence of most adverse cardiovascular events appears to follow a circadian pattern, reaching a peak in the morning shortly after wakening and arising. The activities of many physiologic parameters, including hemodynamic, hematologic and humoral factors, also fluctuate in a cyclical manner over the 24h. It has been suggested that, during the post-awakening hours, the phases of these cycles synchronize to create an environment that predisposes to atherosclerotic plaque rupture and thrombosis in susceptible individuals, thereby accounting for the heightened cardiovascular risk at this time of day. Blood pressure and heart rate are part of this physiologic process, following a clear circadian rhythm characterized by a fall during sleep and a sharp rise upon awakening. This so-called 'morning surge' in blood pressure may act as a trigger for cardiovascular events, including myocardial infarction and stroke. The clinical implication of these observations is that antihypertensive therapy should provide blood pressure control over the entire interval between doses. For agents taken once daily in the morning, the time of trough plasma drug level (and lowest pharmacodynamic effect) will often coincide with the early morning surge in blood pressure and heart rate. For these reasons, chronotherapeutic formulations of drugs and intrinsically long-acting antihypertensive agents provide the most logical approach to the treatment of hypertensive patients since they provide 24 h blood pressure control from a single daily dose as well as attenuating the early morning rise in blood pressure (and in some instances heart rate).


Subject(s)
Blood Pressure/physiology , Cardiovascular Diseases/physiopathology , Circadian Rhythm/physiology , Heart Rate/physiology , Cardiovascular Diseases/diagnosis , Cardiovascular Diseases/therapy , Female , Humans , Male , Risk Factors
16.
Blood Press Monit ; 6(2): 107-10, 2001 Apr.
Article in English | MEDLINE | ID: mdl-11433132

ABSTRACT

BACKGROUND: Non-invasive self blood pressure monitoring has become increasingly popular. To assure the accuracy of devices used for this purpose, all need to be validated independently prior to marketing. The objective of this study was to assess the accuracy of the HEM-907, a new semi-automatic, non-invasive, oscillometric blood pressure monitoring device specifically designed to be used in the clinic or physician's office setting. METHODS: Blood pressure measurements taken employing this device were compared with the results obtained by two experienced observers using a mercury sphygmomanometer on 100 subjects and patients (384 measurements). The limits of agreement were calculated for the device compared with the results of the two observers according to the standards of the Association for the Advancement of Medical Instrumentation (AAMI). RESULTS: The agreement between the two observers was -0.36+/-2.32mmHg for systolic blood pressure and 0.02+/-2.42mmHg for diastolic blood pressure. The agreement between the device and the observers was 1.56+/-4.42mmHg and 3.49+/-4.61mmHg for systolic and diastolic blood pressure respectively. CONCLUSIONS: The Omron HEM-907 satisfied the AAMI criteria for accuracy for a non-invasive blood pressure monitoring device.


Subject(s)
Blood Pressure Monitors/standards , Adult , Aged , Blood Pressure Determination , Female , Humans , Male , Middle Aged , Observer Variation , Reproducibility of Results , Signal Processing, Computer-Assisted
17.
J Hum Hypertens ; 15(7): 475-80, 2001 Jul.
Article in English | MEDLINE | ID: mdl-11464257

ABSTRACT

An 8-week, multicentre (72 sites in the US), double-blind, randomised, parallel group, forced titration study compared the antihypertensive efficacy of candesartan cilexetil and losartan. A total of 611 patients with essential hypertension (diastolic blood pressure 95 to 114 mm Hg) were randomised initially to candesartan cilexetil 16 mg once daily or losartan 50 mg once daily. After 2 weeks of randomised treatment, the doses of candesartan cilexetil and losartan were doubled to 32 mg and 100 mg once daily and continued respectively for 6 weeks. At week 8, candesartan cilexetil lowered the blood pressure (BP) at 24 h (trough), 6 h (peak) and 48 h post dose to a significantly greater extent (P < 0.05) than losartan: candesartan cilexetil lowered trough BP by 13.4/10.5 mm Hg, peak BP by 15.5/12.9 mm Hg and 48-h BP by 10.5/9.9 mm Hg compared to a reduction of trough BP by 10.1/9.1 mm Hg, peak BP by 12.0/9.5 mm Hg, and 48-h BP by 5.9/7.0 mm Hg by losartan. The responder and control rates were numerically higher in the candesartan cilexetil group, but the differences did not reach statistical significance; the responder rates were 58.8% for the candesartan cilexetil group and 52.1% for the losartan group and control rates were 49.0% for the candesartan cilexetil group and 44.6% for the losartan group. Overall, both treatment regimens were well tolerated. A total of 15 of the 611 (2.5%) patients withdrew from the study due to an adverse event, including nine (2.9%) in the candesartan cilexetil group and six (2.0%) in the losartan group. In conclusion, this forced titration study confirms that candesartan cilexetil is more effective in lowering BP than losartan when compared at once daily maximum doses.


Subject(s)
Antihypertensive Agents/administration & dosage , Benzimidazoles/administration & dosage , Biphenyl Compounds/administration & dosage , Hypertension/drug therapy , Losartan/administration & dosage , Tetrazoles , Female , Humans , Hypertension/physiopathology , Male , Prodrugs/administration & dosage , Treatment Outcome
19.
J Hum Hypertens ; 15(2): 135-41, 2001 Feb.
Article in English | MEDLINE | ID: mdl-11317194

ABSTRACT

BACKGROUND: The effect of controlled-onset, extended-release (COER) verapamil on haemodynamic parameters in obese and non-obese patients is evaluated in this analysis. METHODS: Data were pooled from three clinical trials evaluating efficacy and tolerability of COER-verapamil. Hypertensive men and women (stage I to III) were randomised to COER-verapamil (180-540 mg at bedtime) or placebo for 4-8 weeks and stratified according to body mass index (BMI-obese > 28 kg/m2). Efficacy was assessed as change from baseline in blood pressure (BP), heart rate, and rate-pressure product during four time periods throughout the dosing interval. Safety and tolerability were assessed by monitoring all adverse events and changes in metabolic laboratory parameters. RESULTS: Reductions in all haemodynamic parameters were significantly greater following COER-verapamil compared with placebo for all time periods. The haemodynamic effects of COER-verapamil in obese (n = 166, BMI = 32.8 kg/m2) and non-obese patients (n = 115, BMI = 25.0 kg/m2) were similar. COER-verapamil was well tolerated in both subgroups, but the incidence of constipation was significantly less in obese patients (P < 0.001). CONCLUSIONS: COER-verapamil is effective in reducing BP, heart rate, and rate-pressure product independently of BMI.


Subject(s)
Calcium Channel Blockers/administration & dosage , Calcium Channel Blockers/therapeutic use , Chronotherapy , Hypertension/complications , Hypertension/drug therapy , Obesity/complications , Verapamil/administration & dosage , Verapamil/therapeutic use , Aged , Blood Pressure/drug effects , Blood Pressure Monitoring, Ambulatory , Body Mass Index , Delayed-Action Preparations , Female , Heart Rate/drug effects , Humans , Male , Middle Aged
20.
Congest Heart Fail ; 7(6): 319-324, 2001.
Article in English | MEDLINE | ID: mdl-11828178

ABSTRACT

Ambulatory blood pressure monitoring has become a widely used method of blood pressure and heart rate evaluation in the free-living subject. Recently, ambulatory monitoring has become covered by Medicare for the evaluation of "white-coat" hypertension. Although the technique provides only intermittent readings throughout the 24-hour period, average blood pressures obtained in this way correlate well with a variety of hypertensive disease processes and are also a better prognostic marker for future cardiovascular events than office blood pressure. Ambulatory blood pressure averages also correlate well with indices of diastolic dysfunction. In patients with congestive cardiac failure and systolic dysfunction, ambulatory monitoring suggests an impaired circadian blood pressure profile with high nocturnal blood pressure. Further research is needed on the relationship between ambulatory blood pressure and cardiac dysfunction, as well as the impact of observed circadian blood pressure changes on outcome. (c)2001 CHF, Inc.

SELECTION OF CITATIONS
SEARCH DETAIL
...